Phaseline

Targets › CFD

CFD (Complement factor D): drug programs, companies and trials

2 programs from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Hematology, Cardiovascular; next expected readout May 2027.

Serine protease that initiates the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the…. (UniProt, P00746)

Open in Phaseline: the race on CFD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaDanicopan
Complement factor D inhibitor
CFDPhase 3Paroxysmal Nocturnal HemoglobinuriaMay 2027
AstraZenecaALXN2220
Factor D complement inhibitor
CFDPhase 2Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Feb 2029

Conditions

Paroxysmal Nocturnal Hemoglobinuria (2) Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (1)

Modalities

small molecule (1), mixed (1)

Companies

AstraZeneca (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.